Vir Biotechnology to Begin Mid-to-Late Stage Trial of COVID-19 Treatment
California-based Vir Biotechnology plans to launch a phase 2/3 trial this month of VIR-7831, its investigational neutralizing monoclonal antibody for the treatment of COVID-19 patients.
The antibody was shown to neutralize the SARS-CoV-2 virus in preclinical studies. Vir said it also plans to evaluate the drug for the prevention of COVID-19 infections.
The company said preliminary data from the trial will be available before the end of the year.